Literature DB >> 10543752

High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.

M Homma1, A L Jayewardene, J Gambertoglio, F Aweeka.   

Abstract

Ribavirin is an antiviral agent used in the treatment of chronic hepatitis C virus infection. One of the limitations associated with the use of ribavirin is a reversible anemia caused by its accumulation in erythrocytes. Therefore, it is of interest to determine ribavirin levels in erythrocytes, as well as in plasma, as these measurements may be predictive of hematotoxicity. In the present study, we describe a high-performance liquid chromatographic (HPLC) assay for ribavirin in whole blood to estimate concentrations of free ribavirin and phosphorylated anabolites in erythrocytes. Since ribavirin exists primarily as phosphorylated anabolites (mono-, di-, and triphosphates) in erythrocytes, whole-blood extracts were initially dephosphorylated with acid phosphatase. The enzyme-treated samples were subjected to phenyl boronic acid column extraction for cleanup. The purified fraction was analyzed by reversed-phase HPLC, which was optimized for determination of ribavirin levels in whole blood. The recoveries of ribavirin from whole blood ranged from 63.1 to 90.7% at concentrations ranging from 1.67 to 40.0 microM. Intra- and interassay variations estimated at these concentrations were 3.2 to 10.4 and 4.7 to 11.7%, respectively. This method was used to quantitate ribavirin in samples both treated and untreated with acid phosphatase to estimate the extent of intracellular phosphorylation in erythrocytes. The method was also used to evaluate the effects of dipyridamole, a nucleoside transporter inhibitor, on ribavirin disposition in erythrocytes in in vitro experiments.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543752      PMCID: PMC89548     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin.

Authors:  T Thevenot; P Mathurin; J Moussalli; M Perrin; F Plassart; C Blot; P Opolon; T Poynard
Journal:  J Viral Hepat       Date:  1997-07       Impact factor: 3.728

2.  Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

Authors:  T Bizollon; U Palazzo; C Ducerf; M Chevallier; M Elliott; J Baulieux; M Pouyet; C Trepo
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

3.  Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter.

Authors:  S D Patil; L Y Ngo; P Glue; J D Unadkat
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

Review 4.  Nucleoside and nucleobase transport systems of mammalian cells.

Authors:  D A Griffith; S M Jarvis
Journal:  Biochim Biophys Acta       Date:  1996-10-29

5.  Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.

Authors:  S M Jarvis; J A Thorn; P Glue
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

6.  Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus.

Authors:  J J Lertora; A B Rege; J T Lacour; N Ferencz; W J George; R B VanDyke; K C Agrawal; N E Hyslop
Journal:  Clin Pharmacol Ther       Date:  1991-10       Impact factor: 6.875

Review 7.  Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.

Authors:  D T Dieterich; J M Purow; R Rajapaksa
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

Authors:  O Reichard; G Norkrans; A Frydén; J H Braconier; A Sönnerborg; O Weiland
Journal:  Lancet       Date:  1998-01-10       Impact factor: 79.321

9.  Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.

Authors:  B L Robbins; B H Waibel; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

10.  Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Authors:  O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

View more
  12 in total

1.  Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver.

Authors:  Zhongqi Dong; Qing Li; Dong Guo; Yan Shu; James E Polli
Journal:  J Pharm Sci       Date:  2015-02-02       Impact factor: 3.534

2.  Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.

Authors:  Cédric Laouénan; Patrick Marcellin; Martine Lapalus; Feryel Khelifa-Mouri; Nathalie Boyer; Fabien Zoulim; Lawrence Serfaty; Jean-Pierre Bronowicki; Michelle Martinot-Peignoux; Olivier Lada; Tarik Asselah; Céline Dorival; Christophe Hézode; Fabrice Carrat; Florence Nicot; Gilles Peytavin; France Mentré; Jeremie Guedj
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

3.  Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification.

Authors:  Leah C Jimmerson; Michelle L Ray; Lane R Bushman; Peter L Anderson; Brandon Klein; Joseph E Rower; Jia-Hua Zheng; Jennifer J Kiser
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-12-17       Impact factor: 3.205

4.  Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.

Authors:  Tomoe Kobayashi; Shuhei Hige; Katsumi Terashita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuru Nakanishi; Koji Ogawa; Makoto Chuma; Naoya Sakamoto; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2012-03-30       Impact factor: 7.527

5.  Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood.

Authors:  Yoichi Inoue; Masato Homma; Yasushi Matsuzaki; Minoru Shibata; Takuya Matsumura; Takayoshi Ito; Keiji Mitamura; Naomi Tanaka; Yukinao Kohda
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection.

Authors:  Rie Kubota; Takako Komiyama; Naoki Kumagai; Miyuki Kimijima; Keiko Mitsuki; Junko Uetake; Fumihiko Kaneko; Satoshi Tsunematsu; Kanji Tsuchimoto
Journal:  Hepat Res Treat       Date:  2010-09-08

7.  HPLC-MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEM ss cells.

Authors:  Margarita Meléndez; Osvaldo Rosario; Beatriz Zayas; José F Rodríguez
Journal:  J Pharm Biomed Anal       Date:  2009-02-13       Impact factor: 3.935

8.  Ribavirin quantification in combination treatment of chronic hepatitis C.

Authors:  Sylvie Larrat; Françoise Stanke-Labesque; Agnès Plages; Jean-Pierre Zarski; Germain Bessard; Claude Souvignet
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.

Authors:  Harel Dahari; Marianthi Markatou; Marija Zeremski; Ivan Haller; Ruy M Ribeiro; Teresa Licholai; Alan S Perelson; Andrew H Talal
Journal:  J Hepatol       Date:  2007-02-22       Impact factor: 25.083

10.  Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production).

Authors:  Silvia Sookoian; Gustavo Castaño; Diego Flichman; Jerónimo Cello
Journal:  Ann Hepatol       Date:  2004 Jul-Sep       Impact factor: 2.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.